Real-world safety data from the FDA Adverse Event Reporting System suggests that Mounjaro may actually have lower pancreatitis risk compared to some other GLP-1 receptor agonists: Mounjaro (tirzepatide): Adjusted ROR 2.74 (suggests the reporting rate is about 2.7 times higher than would be expected if there was no association) Liraglutide (Saxenda): ROR 4.76 (suggests the reporting rate is about 4.8 times higher than expected, making it higher risk than Mounjaro) Semaglutide (Wegovy/Ozempic): ROR 2.04 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) Dulaglutide (Trulicity): ROR 2.01 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) While these numbers may seem complicated, they suggest that Mounjaros pancreatitis risk is comparable to or lower than that of other medications in the same class, with liraglutide showing a notably higher risk signal

Headaches: Dehydration or blood sugar fluctuations can lead to headaches
Administration Both Tirzepatide and Semaglutide are administered via subcutaneous injection, typically once a week
The nausea lessens as your body gets used to how Ozempic works
Aside from being used to supplement low blood levels, B12 has been used to treat a variety of conditions, including: B12 also boosts energy , improves sleep , increases serotonin to elevate mood , increases focus , and regulates hormone s